CVS Health's Impact on Pharmacy and Insurance Regulation
CVS Health, traditionally viewed as a retail drugstore titan, significantly impacts the healthcare industry through its ownership of Aetna health plans and Caremark, a major pharmacy benefit manager (PBM). Alongside competitors such as Express Scripts by Cigna and Optum Rx by UnitedHealth, Caremark commands roughly 80% of the U.S. pharmacy supply chain. This dominance allows these PBMs to largely control prescription drug availability and cost-sharing for the majority of Americans.
CVS's comprehensive model, combining health insurance, retail pharmacies, and a powerful PBM, has fueled its rise on the Fortune 500 list. However, critiques of this integration suggest it contributes to the closure of independent pharmacies. In Tennessee, 815 pharmacies have shut down over the past decade, a trend some legislators link to the competitive pressures exerted by vertically integrated corporations like CVS.
Legislative Responses to Industry Dynamics
In response, legislative action is gaining momentum in various states. Tennessee lawmakers Sen. Bobby Harshbarger and Rep. Rick Scarbrough have proposed Senate Bill 2040 to mitigate these issues. The bill aims to dismantle the vertical integration within the industry by prohibiting co-ownership of pharmacies and PBMs, requiring entities to divest such operations by January 1, 2028.
CVS strongly opposes this bill, claiming that its implementation might result in store closures throughout Tennessee. The company has used multiple media channels to argue that the forced divestment could seriously impact its operations and workforce. Conversely, proponents of the bill claim it merely requires structural changes, not business shutdowns.
Audit Findings and Legal Challenges
The debate around the bill is supported by findings like the 2024 Tennessee Department of Commerce and Insurance audit, which highlighted unfair pricing practices by CVS Caremark. Issues such as higher charges to health plans than payouts to pharmacies, coupled with litigation alleging kickbacks for formulary placements, underscore the contentious nature of PBM operations.
Legal challenges are anticipated, drawing parallels to similar setbacks faced by an Arkansas law targeting PBM and pharmacy co-ownership, which encountered judicial obstruction over interstate commerce concerns. Tennessee lawmakers prepare for potential litigation as the bill progresses.
Despite opposition, the Tennessee bill is advancing through legislative channels, having recently passed the Senate Health and Welfare Committee with strong support. This reform is part of larger efforts to enhance regulatory compliance and transparency in the insurance and pharmaceutical sectors. Additional testimony from independent pharmacists highlights the disparities in reimbursement practices that significantly affect their viability, fueling calls for legislative intervention.